| Identification | Back Directory | [Name]
D-Tetrandrine | [CAS]
518-34-3 | [Synonyms]
Conba
Jinake
Trandrine
fanchinine
TETRANDRIN
sinomeninea
TETRANDRINE
hanfangchin A
d-tetrandrine
(+)-TETRANDRINE
(S,S)-(+)-TETRANDRINE
TETRANDRINE, (S,S)-(+)
Tetrandrine(Fanchinine)
(S S)-(+)-TETRANDRINE 98%
TETRANDRINE, (S,S)-(+)-(RG)
Tetrandrine(Fanchinine,NSC 77037)
tetramethoxy-4,17-dimethyl-,(4aS,16aS)-
6,6',7,12-TETRAMETHOXY-2,2'-DIMETHYLBERBAMAN
(1B)-6,6',7,12-TETRAMETHOXY-2,2'-DIMETHYLBERBAMAN
(1β)-6,6',7,12-tetramethoxy-2,2'-dimethylberbaman
6’,7,12-tetramethoxy-2,2’-dimethyl-(1-beta)-berbama
6,6',7,12-tetramethoxy-2,2'-dimethyl-1-beta-berbaman
D-Tetrandrine
6,6',7,12-Tetramethoxy-2,2'-dimethyl-1-beta-berbaman
6,6',7,12-Tetramethoxy-2,2'-dimethyl-9',10',11',12',13',14'-hexadehydro-9',10',11',12',13',14'-hexahydroberbaman
16H-1,24:6,9-Dietheno-11,15-metheno-2H-pyrido[2',3':17,18][1,11]dioxacycloeicosino[2,3,4-ij]isoquinoline,3,4,4a,5, 16a,17,18,19-octahydro-12,21,22,26-
16H-1,24:6,9-Dietheno-11,15-metheno-2H-pyrido[2',3':17,18][1,11]dioxacycloeicosino[2,3,4-ij]isoquinoline, 3,4,4a,5,16a,17,18,19-octahydro-12,21,22,26-tetramethoxy-4,17-dimethyl-, (4aS,16aS)- | [EINECS(EC#)]
683-095-7 | [Molecular Formula]
C38H42N2O6 | [MDL Number]
MFCD00082551 | [MOL File]
518-34-3.mol | [Molecular Weight]
622.75 |
| Chemical Properties | Back Directory | [Melting point ]
219-222 °C(lit.)
| [alpha ]
285 º (c=1, CHCl3) | [Boiling point ]
662.81°C (rough estimate) | [density ]
1.1528 (rough estimate) | [refractive index ]
1.5300 (estimate) | [storage temp. ]
Sealed in dry,2-8°C | [solubility ]
Chloroform (Slightly), Methanol (Slightly, Heated) | [form ]
solid
| [pka]
7.70±0.20(Predicted) | [color ]
Off-White | [λmax]
283nm(EtOH)(lit.) | [Merck ]
13,9303 | [LogP]
3.550 (est) |
| Hazard Information | Back Directory | [Chemical Properties]
White powder | [Usage]
analgesic, antineoplastic, antihypertensive, lymphotoxin | [Description]
Recently it has been discovered that pronounced drug-dependence and related
toxic effects occur in both dogs and rhesus monkeys with this alkaloid on
intravenous injection with a dose of 10-150 mg/kg. When rapidly injected, the
acute hypotensive effect is very marked and fatal at once. Following drug
administration at toxic levels it is found that severe local tissue reaction
heptaotoxicity and lymphoid necrosis occurs. At the highest dosage level there
is a very definite nephrotoxicity in monkeys and some indications of this in
dogs. The evidence available suggests that monkeys are less sensitive to
hepatotoxicity with this drug than dogs. | [Physical properties]
Appearance: Needle-like crystals (ether). Solubility: Hardly soluble in water and
petroleum ether; soluble in ether and some organic solvents. Melting point: 219–
222?°C. Specific optical rotation: 285° (c?=?1, CHCl3); sensitive to light. | [History]
Recent studies have shown that tetrandrine has a variety of biological effects and
very good applicational prospects in the treatment of fibrosis and portal vein and
pulmonary hypertension, the regulation of immunologic function, as well as the
prevention and treatment of tumor.
As early as 1988, tetrandrine has been found having the effect on blocking the
Ca2 + channel and was quickly applied into the pharmacological research in the field
of cardiovascular and inflammatory diseases. Results from a large number of
studies have shown that tetrandrine has good effects on antihypertension, arrhythmia, myocardial ischemia, inflammation, and so on. As a traditional Chinese
calcium antagonist, tetrandrine has a broad prospects in clinical applications of cardiovascular and inflammatory diseases.In the early 1990s, the application of tetrandrine was extended. During that time,
researchers conducted many studies about its protective effects on liver, lung, and
mitochondria, which opened a new field for the treatment of liver disease. In
2002, it was found that tetrandrine can inhibit the synthesis of DNA and RNA in
tumor cells, which provided a new method for the treatment of cancer.
At present, the prevention and treatment effects of hypertension, fibrosis, digestive diseases, tumors, rheumatoid arthritis, and other autoimmune diseases of tetrandrine have been confirmed, as well as the function of reducing portal hypertension
and pulmonary hypertension, while its other pharmacological effects are to be
explored in further study. | [Uses]
analgesic, antineoplastic, antihypertensive, lymphotoxin | [Definition]
ChEBI: (+)-Tetrandrine is a member of isoquinolines and a bisbenzylisoquinoline alkaloid. | [Indications]
This product is included in national standards for chemical drugs (Volume 14),
British Pharmacopoeia (2017), and European Pharmacopoeia (9.0th ed.).
Tetrandrine is used for the treatment of mild to moderate hypertension and
hypertensive crisis, rheumatism, silicosis, etc. | [Pharmacology]
Tetrandrine has analgesic, anti-inflammatory, and anti-allergic effects and has a
wide range of usage on the cardiovascular system owing to its antihypertensive,
anti-myocardial ischemia/reperfusion injury and antiarrhythmic effects. It can
inhibit the platelet aggregation induced by ADP, collagen, and arachidonic acid
in?vitro and can also restrain the platelet adhesion and thrombosis (in rabbits).
Tetrandrine also has anticancer effects. Studies have shown that tetrandrine has a
strong inhibitory effect on the DNA and RNA synthesis in L7712 and S180 (cancer
cells), which can significantly suppress the growth of Wacker sarcoma W256.
Besides that, tetrandrine has the ability to relax the striated muscle, and its methyl
iodide or methyl bromide derivatives can also affect the muscles. Notably, tetrandrine can prevent silicosis and has a preferable outcome on the clinical treatment of
such disease. In addition, tetrandrine also owns antipyretic, diuretic, and antiallergic shock effects. | [Clinical Use]
Tetrandrine is used for the treatment of hypertension, angina, termination of paroxysmal supraventricular tachycardia, pulmonary fibrosis, and other diseases in clinical application, and it also has strong antitumor effects. Tetrandrine was also
approved for lowering blood glucose and free radical damage; its treatment effect
on silicosis is significant and superior to conventional immunosuppressive and cytotoxic drugs. | [References]
Gralla, Coleman, Jonas, Cancer Chemother. Rep., Pt. 3, 5(1), 79 (1974) |
|
|